A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Metabolic Solutions Development Company
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Diagnosis of Type 2 Diabetes naive or on metformin

• Male and female (postmenopausal or surgically sterilized), 18 to 70 years of age.

Exclusion Criteria:

• Use of diabetes medications other than metformin.

• History of heart failure or previous myocardial infarction.

• Blood pressure great than 160/100 mmHg.